ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 141 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,768,073 | +26.9% | 512,696 | +35.3% | 0.00% | 0.0% |
| Q1 2024 | $3,756,395 | -54.6% | 379,051 | -85.2% | 0.00% | -50.0% |
| Q4 2023 | $8,265,182 | +385.6% | 2,558,880 | +698.3% | 0.00% | +300.0% |
| Q3 2023 | $1,702,115 | +1439.7% | 320,549 | +2663.4% | 0.00% | – |
| Q2 2023 | $110,548 | +1024.1% | 11,600 | -98.3% | 0.00% | -100.0% |
| Q4 2022 | $9,834 | -99.4% | 664,447 | +673.5% | 0.01% | +400.0% |
| Q3 2022 | $1,641,000 | -14.9% | 85,897 | -14.2% | 0.00% | 0.0% |
| Q1 2022 | $1,928,000 | +163.7% | 100,126 | +227.0% | 0.00% | – |
| Q3 2021 | $731,000 | +67.3% | 30,618 | +102.9% | 0.00% | – |
| Q1 2021 | $437,000 | -90.3% | 15,093 | -90.6% | 0.00% | -100.0% |
| Q4 2020 | $4,503,000 | +401.4% | 160,094 | +422.5% | 0.00% | +200.0% |
| Q3 2020 | $898,000 | +14.5% | 30,642 | +18.1% | 0.00% | 0.0% |
| Q2 2020 | $784,000 | +121.5% | 25,939 | +118.3% | 0.00% | 0.0% |
| Q1 2020 | $354,000 | – | 11,884 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
| Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
| Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
| Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
| Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
| Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
| Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
| RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |